Physician profile
Danny Mcclure
NPI 1073855409
$255,064.28
in general payments reported to CMS, 2019-2025
30 companies · $79K in 2025
The $79K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $475 · 2021: $1,645 · 2022: $9,511 · 2023: $81K · 2024: $84K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Consulting Fee: $52K · Honoraria: $31K · Travel and Lodging: $19K · Food and Beverage: $12K · Education: $66.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $129,482.00 |
| Consulting Fee | $52,401.50 |
| Honoraria | $30,925.00 |
| Travel and Lodging | $18,829.67 |
| Food and Beverage | $11,594.56 |
| Education | $66.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $84,247.21 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $71,228.81 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $56,992.39 | 2021-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $33,065.42 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Biogen, INC. | $2,017.69 | 2023-2024 | Zurzuvae |
| Abbvie INC. | $1,540.34 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $905.79 | 2020-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $795.74 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $520.39 | 2020-2022 | |
| Almatica Pharma LLC | $511.32 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $505.48 | 2022-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $499.06 | 2020-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $400.51 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Bausch Health US, LLC | $373.64 | 2021-2024 | Aplenzin |
| Vanda Pharmaceuticals INC. | $349.57 | 2021-2024 | Fanapt, Hetlioz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $233.38 | 2022-2024 | Azstarys |
| Eisai INC. | $156.20 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $116.56 | 2021-2023 | Austedo, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $113.08 | 2021-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $83.28 | 2022-2024 | Quviviq |
| Allergan, INC. | $79.32 | 2020 | |
| Tris Pharma INC | $72.22 | 2020-2023 | Dyanavel Xr |
| Harmony Biosciences LLC | $54.79 | 2022-2023 | Wakix |
| Noven Therapeutics, LLC | $49.54 | 2024 | Xelstrym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.17 | 2023 | Rexulti |
| Adlon Therapeutics L.P. | $41.01 | 2020-2021 | |
| Tempus Ai, INC | $19.27 | 2024 | Tempus Pixel |
| Amgen INC. | $18.77 | 2019 | |
| Gilead Sciences, INC. | $18.75 | 2019 | |
| Merck Sharp & Dohme LLC | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.